
LENZ Stock Forecast & Price Target
LENZ Analyst Ratings
Bulls say
LENZ Therapeutics has successfully completed a comprehensive clinical program, including three Phase 3 trials under its CLARITY program, demonstrating strong efficacy and safety that position it favorably within the market. The company is expected to experience continued growth in baseline annual spending levels, potentially expanding beyond FY27, which indicates increasing demand for its therapeutic offerings. Furthermore, financial forecasts project that LENZ will achieve profitability by 2028, bolstered by plans to enhance its sales force in response to positive trial outcomes.
Bears say
LENZ Therapeutics faces significant commercial challenges in changing consumer behavior regarding the treatment of presbyopia, which could limit market acceptance of its product, Vizz. Additionally, the company's lack of a diversified pipeline beyond Vizz raises concerns about long-term growth potential and reliance on a single product for revenue generation. Moreover, competitive dynamics and the risk of generic challenges to Vizz's intellectual property may further hinder the company's market position and financial prospects.
This aggregate rating is based on analysts' research of LENZ Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
LENZ Analyst Forecast & Price Prediction
Start investing in LENZ
Order type
Buy in
Order amount
Est. shares
0 shares